Oruka Therapeutics, Inc. ORKA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $49.52M-40.7% | $46.94M-23.8% | $91.25M+134% | $65.4M+332% | $83.57M+201% | ||
| $107.12M— | $142.54M— | $151.76M— | —— | —— | ||
| $395.25M+12.3% | $343.86M-8.8% | $355.16M-14.0% | $332.01M+882% | $352.08M+35,208,200% | ||
| $318K+100% | $288K+77.8% | $253K+58.1% | $174K+4,250% | $159K+2,171% | ||
| —— | —— | —— | —— | —— | ||
| $504.48M+33.8% | $488.62M+23.4% | $509.25M+23.0% | $357.42M+956% | $377.11M+37,711,100% | ||
| $16.63M+41.9% | $15.37M+17.9% | $20.97M+16.2% | $12.11M+853% | $11.72M+641% | ||
| $17.76M+43.4% | $16.69M+20.9% | $22.46M+19.0% | $13.78M+984% | $12.39M+683% | ||
| 545M0.0% | 545M0.0% | 545M0.0% | 545M+3,892,757% | 545M+738% | ||
| -$220.98M-111% | -$189.16M-126% | -$159.57M-175% | -$129.3M+33.2% | -$104.72M+45.1% | ||
| $486.72M+33.4% | $471.93M+23.5% | $486.79M+42.2% | $343.64M+1,286% | $364.73M+36,472,400% | ||
| $504.48M+33.8% | $488.62M+23.4% | $509.25M+23.0% | $357.42M+956% | $377.11M+37,711,100% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Oruka Therapeutics, Inc.'s total assets?
- Oruka Therapeutics, Inc. (ORKA) holds $504.5M in total assets, up 33.8% year over year.
- How much debt does Oruka Therapeutics, Inc. have?
- Oruka Therapeutics, Inc. carries $1.8M in total debt against $486.7M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Oruka Therapeutics, Inc. have?
- Oruka Therapeutics, Inc. holds $49.5M in cash and equivalents.
- Can Oruka Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 23.76 — current assets exceed current liabilities.
- Where does Oruka Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.